Castleark Management LLC Has $47.69 Million Stock Position in Gilead Sciences, Inc. $GILD

Castleark Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 342,150 shares of the biopharmaceutical company’s stock after purchasing an additional 64,822 shares during the period. Gilead Sciences accounts for approximately 1.6% of Castleark Management LLC’s holdings, making the stock its 14th biggest holding. Castleark Management LLC’s holdings in Gilead Sciences were worth $47,685,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Orbimed Advisors LLC bought a new stake in shares of Gilead Sciences during the first quarter worth approximately $8,306,000. Intelligence Driven Advisers LLC raised its position in shares of Gilead Sciences by 57.5% during the 1st quarter. Intelligence Driven Advisers LLC now owns 4,562 shares of the biopharmaceutical company’s stock valued at $636,000 after acquiring an additional 1,665 shares during the last quarter. Gateway Wealth Partners LLC lifted its stake in shares of Gilead Sciences by 152.8% in the 1st quarter. Gateway Wealth Partners LLC now owns 10,298 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 6,225 shares during the period. OMERS ADMINISTRATION Corp boosted its position in shares of Gilead Sciences by 1,456.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 1,163,062 shares of the biopharmaceutical company’s stock worth $162,096,000 after purchasing an additional 1,088,354 shares during the last quarter. Finally, Van Diest Capital LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $286,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 77,000 shares of company stock valued at $9,978,740. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $129.31 on Monday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The business’s 50-day simple moving average is $129.55 and its 200-day simple moving average is $135.62. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The stock has a market capitalization of $160.55 billion, a PE ratio of 17.62 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the company posted $1.81 EPS. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Citigroup increased their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Royal Bank Of Canada reduced their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Finally, Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.33.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.